Posted on

Mindset Pharma to Participate in Upcoming Conferences in May 2022

Mindset Pharma to Participate in Upcoming Conferences in May 2022

TORONTO, May 04, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that James Lanthier, CEO, and Joseph Araujo, CSO of Mindset, will participate in two upcoming conferences:

  • The 2nd Annual Psychedelic Therapeutics & Drug Development Conference to be held at the Westin Arlington Gateway in Arlington, VA on May 23-24, 2022. Mr. Lanthier will present “The Importance of Next Generation Psychedelic Drugs in Treating Mental Health Affliction” on Monday, May 23rd at 1:25 p.m. ET. To attend, register here.
  • H.C. Wainwright Global Investment Conference to be held at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022. Mr. Lanthier and Mr. Araujo will participate in a fireside chat with Patrick Trucchio, H.C. Wainwright Research Analyst, on Wednesday, May 25th at 3:00 p.m. ET. To attend, register here.

For more information about the conferences, or to schedule a one-on-one meeting with Mindset management, please contact your appropriate representative directly, or send an email to KCSA Strategic Communications at Mindset@kcsa.com.

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development for its short-duration compounds, Mindset Families 2 & 4.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788
​​
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds

TORONTO, April 19, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced today the filing of a new provisional patent application that covers new chemical entities (NCEs) that expand the Company’s next-generation DMT and 5-MeO-DMT, or ‘Family 4’, platform, currently under development.

This new patent application exemplifies the Mindset corporate strategy to broaden the therapeutic psychedelic toolbox for patients with mental health disorders who are waiting for transformative medicines and covers novel chemical space while maintaining the functionality of traditional psychedelics.

“As we get more human clinical data from first generation psychedelic drugs, we will unravel how different patients respond to different psychedelic therapies. Our expectation is that different patients will respond to different treatments and paradigms. In an effort to build a toolbox that helps the most patients, Mindset continues to build out its patent portfolio. The Mindset ‘Family 4’ compounds have shown promise in efficacy and safety at a range of doses compared to first-generation DMT and 5-MeO-DMT compounds based on rodent pre-clinical models. Our strong IP position on this family enhances their commercial viability,” said James Lanthier, CEO of Mindset. “We are working hard to bring these innovative mental health solutions to the clinic as fast as possible to waiting patients with our collaborators at the McQuade Center for Strategic Research and Development (MSRD).”

Mindset has a broad IP footprint in the psychedelic space with novel chemical entities in development that mimic the functionality of first-generation psychedelic medicines and have optimized pharmacological and safety profiles to address diverse in-clinic needs. The Company uses a differentiated battery of highly specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development for its short-duration compounds, Mindset Families 2 & 4.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

About the McQuade Center for Strategic Research and Development (MSRD)
Established in 2019, by the Otsuka pharmaceutical business in the U.S., the mission of MSRD is to search for, identify, and fund innovative early-stage research and development programs that have the potential to build the future portfolio of Otsuka products.

Otsuka is dedicated to investing in innovative and creative products in areas of unmet need and MSRD was created as an extension of this commitment to support and identify early-stage opportunities that can change the landscape of treatments for mental illness and renal disorders. For more information, please visit https://msrd-us.com/.

Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders

TORONTO, March 17, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.

Dear Fellow Shareholders:

As we continue to diligently advance our development pipeline, I would like to take a moment to provide an update on our efforts, highlighting our current partnership with the McQuade Center for Strategic Research and Development (MSRD), a member of the global Otsuka family of pharmaceutical companies, our clinical strategy, and development progress across our pipeline of innovative compounds, which provide a de-risked and well-supported path to the clinic.

MSRD Partnership Validates Mindset’s Psychedelic Drug Development Approach and Provides Ongoing Funding

The partnership with MSRD is a major milestone, not only for Mindset but for the broader medical psychedelic industry. This partnership represents a bridge from traditional big Pharma to the new emerging world of psychedelic medicine, which is an industry first. The fact that Mindset spearheaded the first partnerships with big pharma is a testament to our world class innovations and quality of our science and rigorous drug development and validates our strategy for second generation, optimized drug discovery approach.

This partnership provides ongoing funding of development expenses needed to bring clinical candidates from Mindset’s Families 2 and 4 of next-generation psilocybin and 5-MeO-DMT compounds, respectively, through Phase 1a and Phase 1b human clinical trials, and in addition, a payment to Mindset in the amount of US$5 million. This collaboration supports both Mindset and Otsuka’s mission to provide mental health solutions to a massive, underserved, population.

MSRD has extensive regulatory and clinical expertise that will be instrumental in developing a successful human clinical framework. We are excited to further collaborate and explore additional opportunities with MSRD with the aim of broadening access to safe and effective mental health treatments.

Development Platform Enables Multiple Clinical Opportunities for a Variety of Modalities

In addition to our Families 2 and 4 compounds, we continue to evaluate and collect a strong critical data package for our psilocybin-inspired Families 1 and 3 drug candidates.

In Family 1, we identified a lead drug candidate, MSP-1014, which we believe is well-suited to address Treatment-Resistant Depression and End-of-Life Cancer Angst. In preclinical studies, MSP-1014 has demonstrated an improved efficacy and safety profile compared to first-generation psilocybin. Due to its differentiated characteristics, it is considered a new chemical entity (NCE) and we have developed a patent strategy to protect this asset. Early in 2022, we secured a leading contract manufacturer to produce pharmaceutical grade batches of MSP-1014 for IND-enabling studies and subsequent human phase 1 clinical trials l. While we continue collecting data, we are pursuing development partners to support the clinical process.

In Family 3, we identified compounds that have potential to treat a range of mental health disorders in the form of daily, take-home, medications. Our preclinical data suggests that, a range of doses may be sub-hallucinogenic doses, and we plan to examine this class of compounds for pro-cognitive benefits. The ability to provide pro-cognitive solutions without a psychedelic effect will suit vulnerable patient populations such as juvenile ADHD, Alzheimer’s disease, and a range of other psychiatric disorders s. In late 2021, we filed an international patent to cover our Family 3 compounds. We plan to continue studying the effects of our Family 3 compounds through further preclinical animal models, but are extremely pleased and encouraged by our initial results.

Scientific Team with Expertise in Developing Novel CNS Drugs and Strong Industry Ties

Mindset’s drug development program is led by its Chief Scientific Officer, Joseph Araujo, who brings over 20 years of research experience supporting CNS development programs, as well as executive experience at numerous biotech companies. Dr. Malik Slassi, is the SVP of Innovation at Mindset with over 30 years of Pharma and Biotech R&D and management experience, previously the founder, President & CSO of Fluorinov Pharm, which was acquired by Trillium Therapeutics in 2016.

Recently, Mindset hired Dr. Fiona Randall, as SVP of External Alliances and Scientific Strategy to support the Company’s partnership strategy. Dr Randall is a trained neuroscientist with worldwide research and development experience in both neurological research and alliance management and execution.

I am extremely encouraged with the progress we’ve made so far in bringing novel mental health therapies one step closer to patients in need. We have a strong team and alliances in place to expedite our time-to-market and de-risk our drug development programs. We will continue to work hard on the research and development side to unlock new discoveries so that we can provide better insight into the pharmacological potential of psychedelic medicines, both for the industry at large and, one day, to help patients overcome a range of psychiatric disorders.

Sincerely,

James Lanthier
Chief Executive Officer

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788
​​
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions

Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions

TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that, under its Co-operative Psychedelics Evaluation Platform (“COPE”) program with InterVivo Solutions Inc. (“InterVivo”), the Company has identified new pharmacological insights related to the mechanisms of action and bioavailability of 5-MeO-DMT and other first generation psychedelics. Specifically, Mindset has further developed standard pharmacokinetics and drug discrimination data and protocols across LSD, psilocybin, 5-MeO-DMT, and now psilocin.

Comparisons of psilocybin and 5-MeO-DMT benchmarking data have revealed potential differences in the mechanism of action related to the hallucinogenic experience of 5-MeO-DMT versus psilocybin. Furthermore, data suggests that the oral bioavailability of 5-MeO-DMT increases at higher doses in rodents.

“In rodent drug discrimination studies, 5-HT2A antagonists completely block the ability of rats to perceive psilocybin, whereas the same antagonists do not completely block the effects of 5-MeO-DMT, suggesting that the perceptual experience of 5-MeO-DMT is due not only to 5-HT2A receptor agonism,” said Joseph Araujo, Chief Scientific Officer of Mindset. “Pharmacokinetics studies also show 5-MeO-DMT is not orally bioavailable at low doses, but at higher doses, 5-MeO-DMT is bioavailable and its half-life is prolonged, indicating that its metabolism is saturable. This exemplifies the importance of studying a range of doses of psychedelics for benchmarking purposes.”

“Mindset is developing a spectrum of differentiated, next-generation medical psychedelics with the goal of improving several factors compared to first-generation psychedelic drugs,” said James Lanthier, CEO of Mindset. “Thanks to this detailed benchmarking data, we’re better positioned to pre-clinically evaluate and assess drug candidates, which are essential towards reaching our treatment goals.”

The COPE Program is a translational testing platform developed in cooperation with InterVivo to introduce an industry standard against which the performance and efficacy of breakthrough psychedelic medicines are compared and assessed. Through this platform, Mindset and InterVivo intend to establish the first comprehensive psychedelics benchmark reference data set by evaluating a broad range of psychedelic drugs through a proprietary program of in vivo tests conducted at InterVivo’s facility. The COPE platform is anticipated to represent an invaluable tool to guide the development of next-generation psychedelic compounds and improve patentability and value of new potential drug assets.

To watch a video of Mindset’s CEO discussing the announcement in greater detail, please visit: https://youtu.be/kS6Rc0BhIK4

About InterVivo Solutions Inc.
InterVivo Solutions is Canada’s top neuroscience contract research organization, offering translational research services with a focus on next-generation neuroscience drug discovery. InterVivo and its sister company, Transpharmation, offer a wide range of contract services that are focused on discovery and development of neurological and neuropsychiatric new chemical entities including in vivo proof of concept, drug metabolism, pharmacokinetics and early safety research studies for a global client base.

www.intervivo.com / www.transpharmation.co.uk      

About Mindset Pharma Inc.

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788
​​
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy

Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has appointed Fiona Randall, B.Sc., Ph.D., a trained neuroscientist with worldwide research and management experience, as Senior Vice President of External Alliances and Scientific Strategy.

“We have a tremendous opportunity to accelerate Mindset’s growth through strategic partnerships. With Dr. Randall’s extensive experience in both neurological research and alliance management and execution, we’re excited to have her join our team,” said James Lanthier, CEO of Mindset. “Dr. Randall’s industry network and history of successfully managing complex and diverse alliances will play a crucial role in the development of future collaborations for our novel families of next-generations psychedelic compounds.”

Most recently, Dr. Randall founded FireWire Consulting LLC which provides preclinical research and business development services to biopharmaceutical companies. She also served as Senior Director and Interim Head of Alliance Management at Vertex Pharmaceuticals Inc. and Head of External Innovation at Eisai Inc. focusing on how partnering organizations combine strengths to develop innovative therapeutics for patients across a range of diseases. Dr. Randall is a renowned scientist with industry research experience with Eisai, GSK and Merck and has worked in the USA, UK, China and Japan.

“I am very excited to join Mindset at this crucial stage of the company’s remarkable growth journey. Mindset’s approach to drug development is rooted in scientific rigor and its platform of optimized psychedelic compounds broadens the opportunity of delivering mental health solutions both in the clinic and at home. Patients are at the heart of my scientific interests, and I am delighted to be back working in neurology to make medicines for people living with debilitating mental health issues. I look forward to collaborating with the company’s talented team and our strategic partner organizations to accelerate the development of Mindset’s robust portfolio of next-generation psychedelic compounds,” said Dr. Randall.

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its “Microdosing” Compounds

Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its “Microdosing” Compounds

– Mindset’s Family 3 of next-generation psilocybin compounds have demonstrated low levels of activity at the 5-HT2A receptor and long half lives

– Advancing compounds into additional Proof of Concept preclinical studies to measure daily take-home viability

TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has synthesized additional promising candidates from its Family 3 of next generation drug candidates, and will initiate Proof of Concept preclinical studies to further measure the viability of these compounds as daily pro-cognitive take-home medication.

“Our scientists designed and developed a unique class of novel and patentable compounds, our ‘Family 3,’ which have shown promise as a substitute for microdosing approaches due to their low activity at the 5-HT2A receptor. This validates our decision to study the efficacy of these compounds further for pro-cognitive indications associated with neurological and mental health disorders,” said James Lanthier, CEO of Mindset. “If we can demonstrate pro-cognitive benefits at a range of sub-hallucinogenic doses, our compounds have the potential to dramatically broaden the addressable neurology and mental health market we are pursuing while avoiding the hallucinogenic liability associated with traditional approaches. Providing pro-cognitive solutions that do not elicit a psychedelic effect will suit vulnerable patient populations such as juvenile ADHD, Alzheimer’s disease, and a range of others.”

To better understand potential pro-cognitive benefits across a range of sub-hallucinogenic doses, Mindset will initiate a series of in vivo Proof of Concept studies, which will measure motivation and attention. These studies will be critical in establishing the clinical viability of Mindset’s family 3 drug candidates.

Mindset recently announced a first-of-its-kind co-development agreement with the McQuade Center of Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, which fully funds and advances the development of Mindset’s Family 2 & Family 4. Family 3 compounds are potential opportunities for Mindset to partner with other groups to progress its most promising candidates from this family to the clinic.

To watch a video of Mindset’s CEO discussing the announcement in greater detail, please visit: https://youtu.be/4gg0QKfwmrI.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014

Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014

TORONTO, Jan. 25, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has entered into a pharmaceutical manufacturing agreement with a leading contract development and manufacturing organization (CDMO), for the production of pharmaceutical grade batches of Mindset’s next-generation psilocybin drug candidate, MSP-1014.

“Following our co-development announcement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for our short-duration compounds (Mindset Families 2 & 4), we continue to receive interest from potential partners for our wider portfolio of differentiated next-generation drug candidates. As such, our manufacturing agreement with a leading CDMO positions MSP-1014 well for partnership opportunities to advance this optimized compound to human clinical trials,” said James Lanthier, Chief Executive Officer of Mindset. “In preclinical trials, MSP-1014 has shown improved efficacy and safety compared to first-generation psilocybin. Also, it has demonstrated pharmacological diversity making it potentially suitable for both in clinic treatment approaches and as a take-home medicine.”

“Notably, MSP-1014 is not a scheduled substance based on current guidance from regulators in Canada and the USA. With MSP-1014’s unique structure and Mindset’s innovative synthesis process, we anticipate a lower cost and more simple manufacturing process than psilocybin that well positions MSP-1014 for rapid commercialization,” concluded Mr. Lanthier.

About Mindset Pharma
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

‍Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized bywords such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Mindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

Mindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it will participate in the H.C. Wainwright BioConnect Conference to be hosted virtually on January 10-13, 2022.

A corporate presentation from James Lanthier, CEO of Mindset, will be available on-demand starting Monday, January 10th at 7:00 a.m. ET. To view, register here.

For more information about the conference, or to schedule a one-on-one meeting with Mindset’s management team, please contact your appropriate representative directly, or send an email to H.C. Wainwright at lk@hcwco.com, or KCSA Strategic Communications at MindSet@kcsa.com.

The Company also announces that it has engaged Emerging Markets Consulting, LLC (“EMC”) to provide investor/public relations services. Based in Orlando, Florida, with affiliates around the world, EMC is an international investor relations firm that brings decades of combined experience in the investor relations industry. EMC’s services are intended to help small and mid-sized public companies establish brand awareness and increase market share to its customer base while improving visibility to the institutional and retail investment community.

Under the terms of the agreement (the “Agreement”), EMC has agreed to provide a combination of content production and strategic digital media services over a 12-month term for a total payment USD $250,000. To the knowledge of the Company, neither EMC nor any of its principals have an ownership interest, directly or indirectly, in Mindset or its securities, and the Company has not granted EMC or its principals any right to acquire such interests. EMC is at arm’s length to Mindset and has no other relationship with Mindset, except pursuant to the Agreement.

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Mindset Pharma Recaps 2021 Milestones and Highlights

Mindset Pharma Recaps 2021 Milestones and Highlights

– Evolving Pipeline of Psychedelic Compounds Focused on Improved Efficacy and Safety

– Advancing MSP-1014 as First Lead Drug Clinical Candidate to IND-Enabling Studies

TORONTO, Dec. 30, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today provided a recap of its 2021 milestones and highlights.

“In 2021, we made significant progress in building our portfolio of next-generation psychedelic compounds showing improved preclinical safety and efficacy of 5-MeO-DMT and psilocybin-based therapies,” said James Lanthier, CEO of Mindset. “As we enter 2022, we are excited to advance these novel therapies towards the clinic as we progress IND-enabling studies for our lead candidate, MSP-1014, and select additional candidates from our other families of compounds. 2021 was, however, just the beginning for Mindset; we are building the industry’s leading drug discovery platform and intend to continue to break new ground in psychedelic drug discovery in order to bring patented, safe and effective therapies to those suffering from a range of mental illnesses and neurological disorders.”

Operational Highlights:

  • Expanded Patent Portfolio: Filed four provisional patent applications bringing the total to eight provisional applications filed to-date. Mindset also has filed four final PCT applications, which cover a broad range of novel, next generation drugs inspired by psilocybin, DMT, & 5-MeO-DMT and a novel psilocybin synthesis and manufacturing method.
  • Advanced First Lead Drug Candidate Toward Clinical Trials: Selected its first lead clinical candidate, MSP-1014, a differentiated psilocybin-based analog, to move forward into investigational new drug (IND)-enabling studies.
  • Growing Library of Novel Compounds: Synthesized over 100 novel compounds in more than 500 in vitro and in vivo studies.
  • Developed First-in-Class Benchmarking: Under the Cooperative Psychedelics Evaluation Platform (“COPE”) program, Mindset and its partner, InterVivo Solutions, continued to develop first-in-class benchmarking data across first-generation psychedelic drugs.
  • Effect Size & Safety Differentiation Driven by Technology Platform: Preclinical data generated across the four families of novel chemical entities resulted in the identification of a platform technology that enhances effect size and improves safety profiles of psychedelic drugs. A provisional patent application was filed in May of 2021.
  • Enhanced Leadership and Advisory Teams: Appointed Dr. Malik Slassi as Senior Vice President of Innovation, Mr. Ian Dean as Director of Preclinical Development, and Drs. Michael Rogawski, Guy Higgins, Joseph Gabriele and Ishrat Husain to its Scientific Advisory Board (SAB).

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.